Jefferies London 2026: Marea Therapeutics' CEO Josh Lehrer describes the ANGPTL4 target for targeting triglycerides (Marea is first in class) and compares and contrasts it to ANGPTL3 and APOE3

From BiotechTV - News · 00:09:17

Show by BiotechTV

The company recently presented phase 2b data at AHA and published in NEJM. Dr. Lehrer also discusses the company's acromegaly program, and more.

More episodes of BiotechTV - News

More episodes

PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.